Antibody Information

General Information of This Antibody

The Activity Data of This Antibody

Antibody Activity Information 1					[1]
Dissociation Constant (Kd)	0.08±0.07	nM	SK-OV-3 cells	CVCL_0532
Antibody Function	Apparent affinity, flow-cytometric binding assay on Skov-3 cells in vitro. The affinities of the conjugates were similar to the affinities of the respective antibodies.
Antibody Antigen Binding Assay	Binding of anti-FR antibodies and their maytansinoid conjugates to cells was evaluated flow-cytometrically by indirect immunofluorescence. Briefly, 2 104 cells per well in a 96-well plate were incubated for 2 hours at 4C with an anti-FR antibody diluted to various concentrations in assay medium [RPMI-1640 supplemented with 2% (w/v) bovine serum albumin (Sigma)]. The cells were than washed with the cold assay medium, stained with fluorescein isothiocyanatelabeled goat anti-murine or anti-human immunoglobulin G (IgG) antibody for 40 minutes at 4C in the dark, washed with the cold assay medium, fixed in a solution of phosphate-buffered saline, pH 7.4 (PBS) containing 1% formaldehyde, and analyzed using a FACSCalibur flow cytometer. The concentration of the antibody achieving half-maximal binding was taken as the apparent affinity (Kd) of the antibody.

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

HuFR1-49-SMCC-DM1 [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	85.00% (Day 12)	High FOLR1 expression (FOLR1+++; 4,500,000 FOLR1 molecules/cell)
Method Description	Five-week-old female CB-17 severe combined immunodeficient (SCID) mice were obtained and quarantined for 7 days prior to study initiation Mice were inoculated subcutaneously with KB cells (1 x10⁷ cells per mouse) resuspended in serum-free culture mediaMice with established KB xenografts were dosed with a single intravenous injection of 200 g of conjugated maytansinoid per kg, equivalent to 10² mg/kg antibody on day 6 after cell inoculationTumor dimensions were measured twice weekly and volume was calculated as (A B2) 05, where A represents the largest and B the perpendicular tumor diameter. Click to Show/Hide
In Vivo Model	FRalpha-positive KB CDX model
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07±0.01 nM	High FOLR1 expression (FOLR1+++; 4,500,000 FOLR1 molecules/cell)
Method Description	Dilutions of conjugates or unconjugated maytansinoid in the appropriate culture medium were added to wells of 96-well flat-bottomed plates containing 1 x10³ cells per well The plates were incubated at 37°C, 6% CO₂ for either 5 days (continuos exposure) or for 4 hours followed by 5-day incubation in conjugate-free medium (short exposure). Cell viability was determined by the WST-8 assay in accordance with the manufacturer's protocol, and IC50 were generated using a sigmoidal dose-response (variable slope) nonlinear regression curve fit. Click to Show/Hide
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

References

Ref 1	IMGN853, a Folate Receptor- (FR)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR-Expressing Tumors. Mol Cancer Ther. 2015 Jul;14(7):1605-13.